Point72 Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Point72 Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-238,900	Closed	-$4.6M	–	4161
2025 Q3	$4.6M	Buy	238,900 +151,400	+173%	+$2.7M	0.01%	1100
2025 Q2	$1.5M	Buy	87,500 +57,500	+192%	+$2.45M	﹤0.01%	1419
2025 Q1	$1.91M	Buy	+30,000	New	+$3.16M	﹤0.01%	1259
2023 Q4	–	Sell	-20,000	Closed	-$2.42M	–	2774
2023 Q3	$2.42M	Sell	20,000 -10,000	-33%	-$1.13M	0.01%	1087
2023 Q2	$3.44M	Buy	+30,000	New	+$3.87M	0.01%	932
2018 Q3	–	Sell	-25,000	Closed	-$3.31M	–	1206
2018 Q2	$3.31M	Sell	25,000 -25,000	-50%	-$2.36M	0.01%	689
2018 Q1	$3.71M	Buy	+50,000	New	+$3.33M	0.02%	633
2016 Q3	–	Sell	-900,000	Closed	-$17.2M	–	846
2016 Q2	$17.2M	Buy	+900,000	New	+$16.7M	0.12%	207

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's SRPT Position: Q1 2026 in Review

Point72 Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 207,513 shares — an estimated $4.02M sold.

Point72 Asset Management first reported a position in SRPT in Q2 2014 and held it in 35 quarters. The position peaked at $202M in Q3 2016. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Point72 Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Point72 Asset Management sold 207,513 Sarepta Therapeutics shares in Q1 2026, an estimated $4.02M.
Point72 Asset Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 35 quarters.
Point72 Asset Management's Sarepta Therapeutics position peaked at $202M in Q3 2016.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.